These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 7611695)

  • 1. Anatomy and mechanisms of neurotensin-dopamine interactions in the central nervous system.
    Lambert PD; Gross R; Nemeroff CB; Kilts CD
    Ann N Y Acad Sci; 1995 May; 757():377-89. PubMed ID: 7611695
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of nonpeptide antagonists to explore the physiological roles of neurotensin. Focus on brain neurotensin/dopamine interactions.
    Rostene W; Azzi M; Boudin H; Lepee I; Souaze F; Mendez-Ubach M; Betancur C; Gully D
    Ann N Y Acad Sci; 1997 Apr; 814():125-41. PubMed ID: 9160965
    [No Abstract]   [Full Text] [Related]  

  • 3. The effects of typical and atypical antipsychotic drugs on neurotensin-containing neurons in the central nervous system.
    Kinkead B; Nemeroff CB
    J Clin Psychiatry; 1994 Sep; 55 Suppl B():30-2. PubMed ID: 7961568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Neurotensin/dopamine interactions].
    Kitabgi P; Hervé D; Studler JM; Tramu G; Rostène W; Tassin JP
    Encephale; 1989; 15 Spec No():91-4. PubMed ID: 2545433
    [No Abstract]   [Full Text] [Related]  

  • 5. Neurotensin: role in psychiatric and neurological diseases.
    Cáceda R; Kinkead B; Nemeroff CB
    Peptides; 2006 Oct; 27(10):2385-404. PubMed ID: 16891042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The neurotensin antagonist SR 48692 attenuates haloperidol-induced striatal Fos expression in the rat.
    Fadel J; Dobner PR; Deutch AY
    Neurosci Lett; 2001 Apr; 303(1):17-20. PubMed ID: 11297813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of neurotensin receptor antagonists on the firing rate of rat ventral pallidum neurons.
    Michaud JC; Gueudet C; Soubrié P
    Neuroreport; 2000 May; 11(7):1437-41. PubMed ID: 10841353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurotensin and dopamine interactions.
    Binder EB; Kinkead B; Owens MJ; Nemeroff CB
    Pharmacol Rev; 2001 Dec; 53(4):453-86. PubMed ID: 11734615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological evidence that neurotensin mediates prolactin-induced activation of tuberoinfundibular dopamine neurons.
    Hentschel K; Cheung S; Moore KE; Lookingland KJ
    Neuroendocrinology; 1998 Aug; 68(2):71-6. PubMed ID: 9705573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of neurotensin in passive avoidance learning in the rat central nucleus of amygdala.
    László K; Tóth K; Kertes E; Péczely L; Ollmann T; Madarassy-Szücs A; Lénárd L
    Behav Brain Res; 2012 Jan; 226(2):597-600. PubMed ID: 21946307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel dopamine receptor subtypes as targets for antipsychotic drugs.
    Sokoloff P; Diaz J; Levesque D; Pilon C; Dimitriadou V; Griffon N; Lammers CH; Martres MP; Schwartz JC
    Ann N Y Acad Sci; 1995 May; 757():278-92. PubMed ID: 7611685
    [No Abstract]   [Full Text] [Related]  

  • 12. Neuropeptide Receptor Ligands for the Treatment of Schizophrenia: Focus on Neurotensin and Tachykinins.
    Griebel G
    Curr Pharm Des; 2015; 21(26):3807-12. PubMed ID: 26044977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Electrophysiological evidence for putative subtypes of neurotensin receptors in guinea-pig mesencephalic dopaminergic neurons.
    Nalivaiko E; Michaud JC; Soubrié P; Le Fur G
    Neuroscience; 1998 Oct; 86(3):799-811. PubMed ID: 9692718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in [
    Rosin C; López Ordieres MG; Rodríguez de Lores Arnaiz G
    Peptides; 2017 Mar; 89():82-89. PubMed ID: 27586561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endogenous neurotensin attenuates dopamine-dependent locomotion and stereotypy.
    Chartoff EH; Szczypka MS; Palmiter RD; Dorsa DM
    Brain Res; 2004 Oct; 1022(1-2):71-80. PubMed ID: 15353215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Neurotensin receptor antagonists and therapeutical perspectives].
    Gully D; Maffrand JP; Soubrié P; Rostène W; Kitabgi P; Le Fur G
    Therapie; 1995; 50(1):5-7. PubMed ID: 7754478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The neurobiology of neurotensin: focus on neurotensin-dopamine interactions.
    Kasckow J; Nemeroff CB
    Regul Pept; 1991 Oct; 36(2):153-64. PubMed ID: 1666685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Typical and atypical antipsychotic drugs target dopamine and cyclic AMP-regulated phosphoprotein, 32 kDa and neurotensin-containing neurons, but not GABAergic interneurons in the shell of nucleus accumbens of ventral striatum.
    Ma J; Ye N; Cohen BM
    Neuroscience; 2006 Sep; 141(3):1469-80. PubMed ID: 16781818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mediation by neurotensin-receptors of effects of neurotensin on self-stimulation of the medial prefrontal cortex.
    Fernández R; Sabater R; Sáez JA; Montes R; Alba F; Ferrer JM
    Br J Pharmacol; 1996 Sep; 119(2):299-302. PubMed ID: 8886412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of the effect of SR48692 on inositol monophosphate, cyclic GMP and cyclic AMP responses linked to neurotensin receptor activation in neuronal and non-neuronal cells.
    Oury-Donat F; Thurneyssen O; Gonalons N; Forgez P; Gully D; Le Fur G; Soubrie P
    Br J Pharmacol; 1995 Sep; 116(2):1899-905. PubMed ID: 8528577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.